Histologic Index News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Histologic index. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Histologic Index Today - Breaking & Trending Today

ChemoCentryx and VFMCRP Provide Topline Results from ACCOLADE Trial of Avacopan in C3 ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ChemoCentryx and VFMCRP Provide Topline Results from ACCOLADE Trial of Avacopan in C3 .
ChemoCentryx, Inc.December 21, 2020 GMT
As in ANCA vasculitis, avacopan demonstrated statistically significant improvement in renal function as measured by eGFR compared to placebo over 26 weeks of blinded treatment
The change from baseline to Week 26 in C3 Glomerulopathy Histologic Index (C3G HI) for Disease Activity (primary endpoint) was not statistically different between the two treatment groups, while the C3G HI for Disease Chronicity (measuring progression of fibrosis) shows significant benefit for avacopan versus placebo ....

Vifor Pharma , Pwww Chemocentryx , Stefan Schulze , Thomasj Schall , Swiss Stock Exchange , European Commission , Drug Administration , Swiss Exchange , Exchange Commission , Vifor Pharma Group , European Medicines Agency , Chemocentryx Inc , Fresenius Medical Care , Histologic Index , Disease Activity , Disease Chronicity , Vifor Fresenius Medical Care Renal Pharma , Glomerular Filtration Rate , Chief Executive Officer , European Patients , Activity Score , Pharma Group , End Stage Renal Disease , Marketing Authorization Application , Annual Report , Private Securities Litigation Reform Act ,

ChemoCentryx and VFMCRP Provide Topline Results from ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate (eGFR)

Share:
As in ANCA vasculitis, avacopan demonstrated statistically significant improvement in renal function as measured by eGFR compared to placebo over 26 weeks of blinded treatment
The change from baseline to Week 26 in C3 Glomerulopathy Histologic Index (C3G HI) for Disease Activity (primary endpoint) was not statistically different between the two treatment groups, while the C3G HI for Disease Chronicity (measuring progression of fibrosis) shows significant benefit for avacopan versus placebo
Avacopan safe and well tolerated in C3G patients
ChemoCentryx and VFMCRP plan to discuss registration pathway with regulatory agencies in US and EU
Conference call today at 4:30 pm Eastern Time ....

United States , Vifor Pharma , Stefan Schulze , Thomasj Schall , Swiss Stock Exchange , European Commission , Drug Administration , Swiss Exchange , Vifor Pharma Group , European Medicines Agency , Chemocentryx Inc , Fresenius Medical Care , Histologic Index , Disease Activity , Disease Chronicity , Vifor Fresenius Medical Care Renal Pharma , Glomerular Filtration Rate , Chief Executive Officer , European Patients , Activity Score , Fibrosis Progression , Kidney Function , Pharma Group , End Stage Renal Disease , Marketing Authorization Application , ஒன்றுபட்டது மாநிலங்களில் ,